Theoretically, in patients whose PSA level is not confounded by the use of hormones or adenocarcinoma outside the radiation field, the study of PSA kinetics after treatment could yield information about the biological effect of radiation on prostate cancer and, potentially, clinical outcome. The gene discussed is KLK3; the disease is Familial prostate cancer.